This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

SIGA Technologies Reports Financial Results For The Fourth Quarter And Year Ended 2010

NEW YORK, March 9, 2011 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today reported its financial results for the fourth quarter and year ended December 31, 2010.

Revenue for the year ended 2010 was $19.2 million compared to $13.8 million in 2009, and the operating loss was $12.7 million compared to $11.9 million in 2009. Net loss per share, which includes non-operational items such as the fair market valuation of certain warrants, was $0.62 and $0.52 for the years ended December 31, 2010 and 2009, respectively.

For the three months ended December 31, 2010, revenue was $3.1 million compared to $4.0 million in the fourth quarter of 2009, and net operating loss was $4.2 million compared to $3.7 million in 2009.

In addition to reporting financial results, SIGA is also reporting that it responded to the Request for Proposal 11-100-SOL-00007 from the Biomedical Advanced Research and Development Authority ("BARDA") prior to the deadline. 

2010 Key Financial Results


For 2010, revenue from research and development ("R&D") grants and contracts was $19.2 million compared to $13.8 million for the year ended December 31, 2009. The increase of $5.4 million is primarily due to a $2.4 million revenue increase for the Company's arenavirus antiviral program and a $2.2 million revenue increase for its broad-spectrum antiviral drug program. Revenue also increased by $900,000 for the Company's ST-246 program. 

Research and Development

For 2010, research and development ("R&D") expenses were $22.6 million, an increase of $5.2 million from $17.4 million recognized for the year ended December 31, 2009. The increase is primarily due to activity in the arenavirus and broad-spectrum antiviral programs. Vendor-related expenses increased $1.8 million for the arenavirus program and $860,000 for the broad-spectrum program. Employee-related compensation costs, including costs related to the arenavirus and broad-spectrum programs, increased $925,000.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.64 0.00%
FB $118.57 0.00%
GOOG $698.21 0.00%
TSLA $241.80 0.00%
YHOO $36.53 0.00%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs